Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2024-09-01
2025-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Pain is commonly experienced by people who are living with advanced (incurable) cancer. There is evidence to suggest virtual reality could help to relieve this pain: however, this evidence is poor quality with the intervention poorly defined. A robustly co-designed intervention, with people who have advanced cancer and experience pain, will facilitate a better evidence-base.
Aim
To develop and refine a virtual reality intervention that will help people living with advanced cancer to manage pain.
Objectives
1. Explore and establish key components of a virtual reality intervention for people with advanced cancer in terms of effectiveness, acceptability and feasibility using in-depth interviews and focus groups with people living with advanced cancer and experiencing pain.
2. Develop and manualise a virtual reality intervention using co-design methodology.
3. User-test the intervention to refine further.
Methods
Multi-method design, incorporating multiple stakeholder perspectives, over three phases:
Phase I. Focus groups or individual interviews with a total of 40 people, from four locations (Brighton, Cardiff, Liverpool, \& London), who have advanced cancer and experience pain.
They will use the virtual reality intervention and give feedback on what resonated with them and what they would change.
Phase II. Four focus groups (one at each study location) with multiple stakeholders. During this stage, the findings from phase 1 will be presented and a manual will be produced that gives guidelines on use of the virtual reality intervention.
Phase III. Up to 20 people living with advanced cancer and pain will user-test the intervention over an eight-week period. During this phase, the investigators will test if/how often the virtual reality is used as part of routine practice in each site and identify any barriers of use.
Anticipated Impact and Dissemination
1. A robustly co-designed intervention, ready for testing in a larger trial, to assess the clinical and cost effectiveness of virtual reality as a form of pain management.
2. Guidelines for the use of virtual reality in a clinical setting.
The results will be published through academic routes (peer-reviewed publications as well as presented at national and international conferences). The investigators will also work with our group of people with lived experience and an oversight committee to establish the best other routes to disseminate the findings to the public e.g., a social media campaign, leaflets to clinical settings, blog and vlog posts.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase I
People living with advanced cancer and experiencing pain.
Participants will complete two interviews. In each interview, they will use a Virtual Reality headset and discuss with the researcher the potential benefits, any changes they would make to the experiences, and how they might use it in practice.
Virtual Reality
A range of virtual reality software, delivered through the "DR.VR" (TM) device.
Phase II
Participants: Staff working at participating sites, technology specialists, Patient and Public Involvement (PPI) representative.
There will be a workshop at each participating site. Participants will work together to manualise the intervention so that it is ready for a feasibility trial and process evaluation.
They will discuss the following:
* Indications of use for virtual reality as a pain therapy
* Frequency of use: recommended number of sessions, duration.
* Barriers or facilitators that might impact the use of virtual reality.
* Pain and other patient-reported outcomes identified.
* What possible longer-term goals of using virtual reality as a pain therapy could include.
* Guidance for specific settings, including safety considerations.
* Operator instructions: patient or operator delivered.
* Infection control management.
No interventions assigned to this group
Phase III
Participants: People living with advanced cancer and experiencing pain.
During this phase, we will implement the recommendations from the manual from phase II. A headset will be available for use on an as needed basis at each study location. Participants will be asked to provide feedback each time they use the headset. Specific for data on pain, the Brief Pain Inventory (BPI) will be completed. This looks at pain severity as well as how much pain impacts their daily life. Whilst the availability of only one headset per site will limit the frequency of use, particularly for those who are outpatients, this is reflective of current availability of virtual reality headsets in each location. This data will generate recommendations for future research and clinical practice, including the consideration of the economic impact.
Virtual Reality
A range of virtual reality software, delivered through the "DR.VR" (TM) device.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Virtual Reality
A range of virtual reality software, delivered through the "DR.VR" (TM) device.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Under the care of the specialist palliative care team or cancer centre
* A documented diagnosis of advanced cancer (Synonyms: "Palliative", "terminal", "incurable", "treatable but not curable") in their medical notes, confirmed by the clinical team.
* Adult (aged 18 years or over)
* Pain score in the last 7 days of ≥1 on Numerical Rating Scale \[0-10\]
* Full visual and auditory abilities
* No restriction in range of head and neck movement
* Capacity to consent to the study
* Fluent in English
* An estimated prognosis of longer than 6 months.
Professional/staff participants will be considered eligible if:
* a registered healthcare professional (doctors, nurses, allied health professionals, psychologists)
* employed by the study or location or by the virtual reality company.
Professional/staff participants will be excluded if:
• They are not employed by the study location, or the virtual reality company
We will document reasons for not participating, where offered.
Exclusion Criteria
* a diagnosis of epilepsy
* are imminently dying
* the clinical team feel it would be detrimental to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Velindre NHS Trust
OTHER_GOV
Lancaster University
OTHER
Brighton and Sussex University Hospitals NHS Trust
OTHER
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicola White, PhD
Role: PRINCIPAL_INVESTIGATOR
University College, London
Ollie Minton
Role: PRINCIPAL_INVESTIGATOR
Brighton and Sussex University Hospitals NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Brighton and Sussex University Hospitals NHS Trust
Brighton, , United Kingdom
Velindre University NHS Trust
Cardiff, , United Kingdom
Marie Curie Hospice, Liverpool
Liverpool, , United Kingdom
St Christophers Hospice, London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
158450
Identifier Type: -
Identifier Source: org_study_id